1.Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation
Journal of International Oncology 2014;41(3):184-187
Reactivation of hepatitis B virus (HBV) in cancer patients with HBV infection during or after chemoradiotherapy can lead to acute liver injury,even death.Antiviral prophylaxis can reduce the occurrence of HBV reactivation and its associated morbidity.However,there is no unified standard to guide antiviral treatment.Therefore,multidisciplinary collaboration and more prospective study should be carried out to identify the individual antiviral treatment plan.
2.Prevention and therapy of small cell lung cancer with brain metastasis
Journal of International Oncology 2014;(8):588-591
Small cell lung cancer with brain metastasis is the most common type in brain metastasis tumors with the poor prognosis. Researches show that prophylactic cranial irradiation is not only effective in the prevention and treatment of limited disease brain metastases of small cell lung cancer,but also effective for extensive disease. Moreover,certain medications such as mannitol,nimustine etc also play an important sup-porting role,but there are many other uncertain parts in terms of prevention and treatment remaining controver-sial and needing further research.
3.Treatment of superior vena cava syndrome caused by malignant tumour
Cancer Research and Clinic 1999;0(05):-
Superior vena cava syndrome(SVCS) is caused by malignant tumour, often showing tumour crisis. The prognosis is bad. It will endanger the life frequently if not cured in time. It is argued which is the preferred treatment on radiotherapy, chemotherapy, surgery or colligate therapy etc. Now we introduce briefly correlated study in the near future, pointting out the colligate therapy trend of SVCS.
4.Late course stereotactic radiosurgery for stage Ⅲ_b squamous cell carcinoma of lung
Jinming YU ; Yonghua YU ; Shoufang GUO
Chinese Journal of Radiation Oncology 1995;0(02):-
Objective To assess the early response and acute side effects of late course stereotactic radiosurgery (LCSR) for stage Ⅲ b lung squamous cell carcinoma. Methods From June 1997 to July 1999, 136 patients with stage Ⅲ b squamous cell carcinoma of lung were treated with the conventional radiotherapy of 40 Gy followed by LCSR to the residual lesion. Stereotactic radiosurgery was given in the 5~6th weeks, 5~8 Gy per fraction with the total doses ranging from 24 to 38 Gy. Results Five patients were excluded from this study due to distant metastases and acute complications. The remaining 131 patients were analyzed to evaluate the early responses and acute complications. Acute radiation induced esophagitis occurred in 41.2% of patients (Grades Ⅰ Ⅱ (RTOG), 4.4% Grade Ⅲ). Acute radiation induced pneumonitis was observed in 16.9 % of patients ( Grades Ⅰ Ⅱ (RTOG),5.2% Grade Ⅲ). The overall response rate (CR+PR) was 86.3% for the primary tumor, and 92.4% for metastatic mediastinal lymph nodes. Conclusions LCSR is well tolerated in most patients with stage Ⅲ b squamous cell carcinoma of lung. The early responses of LCSR in the of tumor are better than the conventional radiotherapy.Remote results await further follow up.
5.Promising method for detection of tumor cell in vivo: photoacoustic flow cytometry
Lei FU ; Yonghua YU ; Jinming YU
Cancer Research and Clinic 2014;26(12):793-796
Photoacoustic flow cytometry (PAFC) is a novel flow cytometry which integrates high-pulse repetition-rate lasers,fast signal acquisition algorithms and focused ultrasound transducers to assess deep vessels.The technical principle is that the cells in blood or lymph flow are irradiated with several laser beams with different wavelengths,then laser-induced PT effects are detected by corresponding schematics.PAFC is characterized by its high efficiency,no invasion and real-time detection,which makes it possible to detect tumor cells in circulation or in lymphatic system dynamically and in real time.So for,it is considered as one of the most promising techniques in cancer research.This article will address the principle,application and several problems of PAFC.
6.Treatment of patients with unresectable liver cancer by a combination of transcatheter arterial infusion and stereotaxic radiotherapy
Yonghua YU ; Jinming YU ; Shoufang GUO
Chinese Journal of General Surgery 1997;0(04):-
ObjectiveTo study the effect of transcatheter hepatic arterial infusion (TAI) and stereotaxic radiotherapy (SR) for unresectable liver cancer. MethodsFrom June 1997 to July 1999, TAI and SR were used to treat 36 patients with unresectable liver cancer. The first step was interventional chemotherapy(TAI) which consisted of CF 300?mg,5-FU 1?000~1?500?mg, CDDP 60~80?mg, and ADM 60~80?mg (or MMC 10~20?mg). Stereotaxic radiotherapy was given after two sessions or between the two sessions of TAI. The planned target volume was encompassed by more than 70%~90% isodose line, tumor dose from 5?Gy to 8?Gy per fraction, total number was 5~8 fractions. ResultsThe total effective rate were 94% and 97% judged by CT at 3 and 6 months respectively. The 1-,2-year survival rates were 85% and 68%,respecctively. ConclusionCompared with radiotherapy alone and interventional chemotherapy alone, the combined therapy results in higher therapeutic effect and longer remission time in patients with unresectable liver cancer.
7.Radiotherapy in comprehensive treatment of gastric cancer
Jia LI ; Yonghua YU ; Xijun LIU
Journal of International Oncology 2011;38(8):614-617
Radiotherapy is an effective mean of treatment of gastric cancer. Combination of radiotherapy and chemotherapy in gastric cancer preoperative, postoperative and palliatie treatments can increase the local control rate and the survival rate of gastric cancer patients. With the development of three-dimensional conformal and intensity modulated radiotherapy, the radiotherapy is being more extensively applied in the comprehensive treatment of gastric cancer.
8.Prediction of response to chemotherapy and (or) radiotherapy in locally advanced non-small cell lung cancer with 18F-FDG PET-CT
Shouhui ZHU ; Yonghua YU ; Yong ZHANG
Journal of International Oncology 2011;38(10):764-767
18 F-FDG PET-CT has been widely used for the diagnosis,staging and assessment of therapeutic response in patients with non-small cell lung cancer (NSCLC).In particular,the technique plays an important role in the prediction of the response to therapy in patients with locally advanced NSCLC.It can dynamically observe the tumor tissue metabolism,and according to the changes of 18 F-FDG uptake by visual or quantitative analysis,before and after treatment,allow prediction of the early efficacy of locally advanced NSCLC with chemotherapy and (or) radiotherapy in clinical or sub-clinical levels.
9.The advances in diagnosis and treatment of non-small cell lung cancer with PET-CT
Xiangrong ZHAO ; Yong ZHANG ; Yonghua YU
Journal of International Oncology 2016;43(2):133-137
PET-CT plays a increasing important role in the treatment of lung cancer.Compared with CT,the advantage of PET-CT is obvious,which is more accuracy when determine a metastasis and identify inflammatory lesions.What's more,on the basis of the accuracy staging,PET-CT change many strategies which were based on traditional image,resulting in improving the treatment effect.While the assessment and prediction of the efficacy by PET-CT also exerted an important influence on the formulation of treatment strategies.
10.The effect comparison of different concentration dexmedetomidine with butorphanol on postoperative analgesia
Yanfeng YU ; Wenyang LIU ; Yonghua QIN
Chinese Journal of Postgraduates of Medicine 2013;36(21):29-32
Objective Through the effect comprison of analgesic calm and side-effect on postoperative analgesia under different concentration dexmedetomidine with butorphanol,to research the best concentration of dexmedetomidine on postoperative analgesia.Methods Ninety patients with lower abdominal surgery with general anesthesia,ASA Ⅰ-Ⅱ grade,were divided into 3 groups by random digits table:group A,group B and group C,each group with 30 cases.The group A received 0.2 μg/ (kg·h) dexmedetomidine.The group B received 0.3 μg/ (kg ·h) dexmedetomidine,both added 0.15 mg/kg butorphanol and 8 mg ondansetron.The group C only received 0.15 mg/kg butorphanol and 8 mg ondansetron.Applied patient controlled intravenous analgesia (PCIA) pump continuous infusion gave total 100 ml,background infusion 2 ml/h,patient controlled analgesia (PCA) 2 ml,lock time 30 min,analgesia was continued 48 h.Below were recorded at 2,6,12,24 and 48 h after the beginning of PCIA:analgesia VAS score,ramsay sedation scale (RSS),adverse reaction.The total number of button pressing of PCA and the consumption of patient controlled liqnid analgesia (PCLA) solution were also recorded.Results There was no statistically significant difference in VAS score after each time point between group A and group B (P> 0.05).The VAS scores after each time point in group A and group B were significantly lower than those in group C [(2.7 ±0.8),(2.6 ± 0.8) scores vs.(3.2 ± 0.9) scores; (1.8 ± 0.6),(1.7 ± 0.6) scores vs.(2.5 ± 0.6) scores; (1.0 ±0.6),(0.9 ±0.7) scores vs.(1.8 ±0.6) scores; (1.0 ±0.5),(0.8 ±0.5) scores vs.(1.4 ±0.5) scores; (0.7 ±0.5),(0.7 ±0.4) scores vs.(1.0 ±0.5) scores,P <0.05].There was no statistically significant difference in RSS score among 3 groups (P > 0.05).The RSS scores after 6,12,24 and 48 h in group A and group B were significantly higher than those in group C [(2.6 ±0.5),(3.5 ±0.6) scores vs.(2.0 ±0.3) scores; (2.9 ± 0.6),(3.8 ± 1.2) scores vs.(2.4 ± 0.3) scores; (2.8 ± 0.7),(3.9 ± 0.7) scores vs.(2.5 ± 0.4)scores; (2.8 ± 0.6),(3.9 ± 0.6) scores vs.(2.5 ± 0.5) scores,P < 0.05],group A was significantly higher than those in group B (P< 0.05).There was no statistically significant difference in rate of hypoxemia among 3 groups (P > 0.05).The rates of nausea and vomit,deliration in group A and group B were significantly lower than those in group C [3.3%(1/30),0 vs.10.0%(3/30) ;0,0 vs.10.0%(3/30),P< 0.05].The rates of hypotension and bradycardia in group B were significantly lower than those in group A and group C[16.7% (5/30) vs.3.3%(1/30),0;20.0%(6/30) vs.3.3%(1/30),0,P< 0.05].The total number of button pressing of PCA 24 h and the consumption of PCLA solution in group C were significantly higher than those in group A and group B [(13.9 ±2.4) times vs.(9.7 ±2.2),(7.4 ± 1.5) times; (60.9 ± 1.8) ml vs.(54.5 ± 1.2),(50.7 ± 0.7) ml,P < 0.05].Conclusion Concentration 0.2 μ g/(kg· h) dexmedetomidine with butorphanol has better effects on postoperative analgesia and calm,less side-effect.